Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA5 | P08648 | 6/20 | 0.76 |
| ▸ | GABRA5 | P31644 | 12/20 | 0.71 |
| ▸ | GABRA1 | P14867 | 5/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL287698 | 0.95 | GABRA5 (0.69) | ITGA5GABRA5GABRA1 | |
| SCHEMBL1777497 | 0.86 | ITGA5 (1.00) | ITGA5GABRA5GABRA1 | |
| SCHEMBL300427 | 0.85 | GABRA5 (0.57) | ITGA5GABRA5GABRA1 | |
| SCHEMBL288655 | 0.85 | GABRA5 (0.57) | ITGA5GABRA5GABRA1 | |
| SCHEMBL289211 | 0.85 | GABRA5 (0.57) | ITGA5GABRA5GABRA1 | |
| SCHEMBL288229 | 0.84 | GABRA5 (0.70) | ITGA5GABRA5GABRA1 | |
| SCHEMBL287977 | 0.84 | GABRA5 (0.55) | ITGA5GABRA5GABRA1 | |
| SCHEMBL13067636 | 0.84 | GABRA5 (0.72) | ITGA5GABRA5GABRA1 | |
| SCHEMBL288205 | 0.84 | GABRA5 (0.72) | ITGA5GABRA5GABRA1 | |
| SCHEMBL296647 | 0.83 | ITGA5 (0.71) | ITGA5GABRA5GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427456-A1 | ISOXAZOLE-PYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-03-14 | — | — | EP | claimed |
| EP-2427456-B1 | ISOXAZOLE-PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-02-05 | — | — | EP | disclosed |
| US-8415379-B2 | Pyridines | HOFFMANN-LA ROCHE INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-8415379-B2 | Pyridines | HOFFMANN-LA ROCHE INC. (US) | 2013-04-09 | — | — | US | disclosed |
| EP-2427456-A1 | ISOXAZOLE-PYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-20100286132-A1 | PYRIDINES | ROCHE PALO ALTO LLC | 2010-11-11 | — | — | US | disclosed |
| US-20100286132-A1 | PYRIDINES | ROCHE PALO ALTO LLC | 2010-11-11 | — | — | US | disclosed |
| WO-2010127976-A1 | ISOXAZOLE-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286132-A1 | PYRIDINES | GABRA5, CHRNA5, GABRA1 | ITGA5 244/4885GABRA5 1/4885GABRA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.